NK细胞亚群CD56bright在帕金森患者外周血中的表达及临床意义

doi:10.6040/j.issn.1671-7554.0.2020.1588

摘要/Abstract

摘要： 目的探讨帕金森病(PD)患者外周血中NK细胞亚群CD56^bright的表达及其临床意义。方法选择2017年10月至2019年12月淄博市中心医院神经内科门诊就诊与住院治疗的PD患者56例(PD组),以及年龄、性别、生活环境相匹配的健康对照者50例(对照组),均为同期健康查体的健康中老年人。采用ELISA法检测PD组患者外周血细胞因子水平;流式细胞术分析NK细胞及其亚群百分比;Hoehn-Yahr分期量值表和帕金森病评定量表评分(UPDRS)对PD组患者进行分层,分析CD56^bright NK细胞比值与PD患者疾病进程的相关性;最后,培养分选的CD56^bright NK细胞亚群,进一步明确其分泌的细胞因子在两组中的差别。结果 PD组血清中细胞因子水平明显高于对照组［IL-1β(t=2.46, P=0.015 4)、IL-6(t=3.19, P=0.001 9)、TNF-α(t=3.37, P=0.001 1)、IFN-γ(t=6.36, P<0.001)］;更重要的是,PD组NK细胞(t=3.13, P=0.007 8)及CD56^bright 细胞亚群(t=4.23, P<0.001)比值增高,且CD56^bright 细胞亚群比值与PD疾病进程呈正相关［Hoehn-Yahr分期(t=3.79, P=0.005 2)、UPDRS评分(t=3.08, P=0.041)］;分选CD56^bright 细胞亚群进行培养,利用LPS刺激后发现PD组可分泌更多的细胞因子［IL-1β(t=2.89, P=0.044 6)、IL-6(t=3.15, P=0.034 7)、TNF-α(t=4.59, P=0.010 1)、IFN-γ(t=4.79, P=0.008 7)］。结论 NK细胞及其CD56^bright亚群在PD患者中高表达,CD56^bright通过分泌细胞因子促进PD的疾病进程,可成为该类疾病新型诊断生物标记物与预后预测新靶点。

关键词: 帕金森病, NK细胞, CD56^bright亚群, 疾病预后, 细胞因子

Abstract: Objective To analyze the expression and clinical significance of circulating CD56^bright subset of NK cellsinpatients with Parkinsons disease(PD). Methods A total of 56 PD patients treated during Oct. 2017 and Dec. 2019 and 50 healthy controls matched in age, sex and living environment were enrolled. The levels of cytokines in the peripheral blood of PD patients were detected with ELISA; the ratios of NK cells and CD56^bright subset were analyzed with flow cytometry; PD patients were stratified with Hoehn-Yahr staging scale and unified Parkinsons disease rating scale(UPDRS); the correlation between the ratio of CD56^bright subset and disease progression was analyzed. Finally, CD56^bright subset was selected and cultured to clarify the differences in cytokines between PD group and control group. Results The levels of cytokines in PD group were significantly higher than those in the control group［IL-1β(t=2.46, P=0.015 4), IL-6(t=3.19, P=0.001 9), TNF-α(t=3.37, P=0.001 1), IFN-γ(t=6.36, P<0.001)］. The ratio of NK cells(t=3.13, P=0.007 8)and CD56^bright subset(t=4.23, P<0.001)in PD group were significantly increased. The ratio of CD56^bright subset was positively correlated with the progression of PD［Hoehn-Yahr staging scale(t=3.79, P=0.005 2), UPDRS(t=3.08, P=0.041)］. PD group could secrete more cytokines than control group after LPS stimulation［IL-1β(t=2.89, P=0.044 6), IL-6(t=3.15, P=0.034 7),TNF-α(t=4.59, P=0.010 1), IFN-γ(t=4.79, P=0.008 7)］. Conclusion NK cells and CD56^bright subset are highly expressed in PD patients. CD56^bright subset can promote the progression of PD by secreting cytokines, and CD56^bright subset can become a new biomarker for diagnosis and a new target for predicting PD prognosis.

Key words: Parkinsons disease, NK cells, CD56^bright subset, Disease prognosis, Cytokines

中图分类号:

R741.04

李湘青,殷欣,赵雪莲,赵培庆. NK细胞亚群CD56^bright在帕金森患者外周血中的表达及临床意义[J]. 山东大学学报 (医学版), 2021, 59(2): 34-40.

LI Xiangqing, YIN Xin, ZHAO Xuelian, ZHAO Peiqing. Expression and clinical significance of circulating CD56^bright subset of NK cells in patients with Parkinsons disease[J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 34-40.

参考文献

[1] Croisier E, Moran LB, Dexter DT, et al. Microglial inflammation in the parkinsoniansubstantianigra: relationship to alpha-synuclein deposition[J]. J Neuroinflammation, 2005, 2:14.doi: 10.1186/1742-2094-2-14.
[2] Markaki I, Bergstrom S, Tsitsi P, et al. Cerebrospinal fluid levels of kininogen-1 indicateearly cognitive impairment in parkinsons disease[J]. Mov Disord, 2020, 35(11):2101-2106.
[3] Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration[J]. Cell, 2010, 140(6):918-934.
[4] Baltus THL, Morelli NR, de Farias CC, et al. Association of -94 ATTG insertion/deletion NFkB1 and c.*126G>A NFkBIA genetic polymorphisms with oxidative and nitrosative stress biomarkers in Brazilian subjects with Parkinsons Disease[J]. Neurosci Lett, 2020, 740:135487.doi:10.1016/j.neulet.2020.135487.
[5] Lahooti B, Chhibber T, Bagchi S, et al. Therapeutic role of inflammasome inhibitors in neurodegenerative disorders[J]. Brain Behav Immun, 2021, 91:771-783. doi: 10.1016/j.bbi.2020.11.004.
[6] Jiang S, Gao H, Luo Q, et al. The correlation of lymphocyte subsets, natural killer cell, and Parkinsons disease: a meta-analysis[J]. Neurol Sci, 2017, 38(8):1373-1380.
[7] Yang M, Zhou Y, Liu L, et al. Decreased A20 expression on circulating CD56(bright)NK cells contributes to a worse disease status in patients with ankylosing spondylitis[J]. Clin Exp Immunol, 2019, 198(1):1-10.
[8] Ilie OD, Ciobica A, McKenna J, et al. Minireview on the relations between gut microfloraand parkinsons disease: further biochemical(oxidative stress), inflammatory, and neurological particularities[J]. Oxid Med Cell Longev, 2020, 2020:4518023.doi: 10.1155/2020/4518023.
[9] Rees K, Stowe R, Patel S, et al. Helicobacter pylori eradication for Parkinsons disease[J]. Cochrane Database Syst Rev, 2011,(11):CD008453.doi:10.1002/14651858.CD008453.pub2.
[10] Tan AH, Mahadeva S, Thalha AM, et al. Small intestinal bacterial overgrowth in Parkinsons disease[J]. Parkinsonism Relat Disord, 2014, 20(5):535-540.
[11] 张忠霞, 马晓伟, 王彦永, 等. 帕金森病模型小鼠黑质纹状体系统氧化应激的增龄性改变[J]. 山东大学学报(医学版), 2014, 52(9): 26-29. ZHANG Zhongxia, MA Xiaowei, WANG Yanyong, et al. Impact of aging on the nigro-strital oxidative stress in a mice model of Parkinsons disease[J].Journal of Shandong University(Health Sciences), 2014, 52(9): 26-29.
[12] Matheoud D, Cannon T, Voisin A, et al. Intestinal infection triggers Parkinsons disease-like symptoms in Pink1(-/-)mice[J]. Nature, 2019, 571(7766):565-569.
[13] 陈思, 王牧川, 任楠楠,等. Parkin基因多态性与山东省汉族帕金森病发病风险的关系[J]. 山东大学学报(医学版), 2015, 53(4): 71-74. CHEN Si, WANG Muchuan, REN Nannan, et al. Relationship between polymorphisms of Parkin gene and the risk of Parkinsons disease in Han nationality of Shandong Province[J]. Journal of Shandong University(Health Sciences), 2015, 53(4): 71-74.
[14] Hirsch EC, Hunot S. Neuroinflammation in Parkinsons disease: a target for neuroprotection?[J]. Lancet Neurol, 2009, 8(4):382-397.
[15] Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinsons disease[J]. Synapse, 2001, 39(2):167-174.
[16] Qin XY, Zhang SP, Cao C, et al. Aberrations in peripheral inflammatory cytokine levels in P arkinsondisease: asystematic review and meta-analysis[J]. JAMA Neurol, 2016, 73(11):1316-1324.
[17] Bokor M, Farago A, Garam T, et al. Antibody-dependent cell-mediated cytotoxicity(ADCC)in Parkinsons disease[J]. J Neurol Sci, 1993, 115(1):47-50.
[18] Vandenhaute J, Wouters CH, Matthys P. Natural killer cells in systemic autoinflammatory diseases: afocus on systemic juvenile idiopathic arthritis and macrophage activation syndrome[J]. Front Immunol, 2019, 10:3089.doi:10.3389/fimmu.2019.03089.
[19] Li T, Gao N, Cui W, et al. Natural killer cells and their function in Takayasus arteritis[J]. Clin Exp Rheumatol, 2020, 124(2):84-90.
[20] Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright)subset[J]. Blood, 2001, 97(10):3146-3151.
[21] 张伟, 王政洁, 闫越颖,等. Tim-3对早期梅毒患者外周血CD56^dim NK细胞的影响及初步机制[J]. 中国免疫学杂志, 2019, 35(16):2005-2010. ZHANG Wei, WANG Zhengjie, YAN Yueying, et al. Expression of Tim-3 on peripheral CD56^dim NK cells of patients with earlysyphilis and its preliminary mechanisms[J]. Chinese Journal of Immunology, 2019, 35(16):2005-2010.
[22] Luci C, Gaudy-Marqueste C, Rouzaire P, et al. Peripheral natural killer cells exhibit qualitative and quantitative changes in patients with psoriasis and atopic dermatitis[J]. Br J Dermatol, 2012, 166(4):789-796.
[23] Jiang W, Chai NR, Maric D, et al. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis[J]. J Immunol, 2011, 187(2):781-790.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed